Share Price and Basic Stock Data
Last Updated: January 1, 2026, 5:06 pm
| PEG Ratio | -109.89 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Drugs Limited operates in the pharmaceuticals sector, with a current market capitalization of ₹3,775 Cr and a stock price of ₹414. The company has demonstrated a fluctuating revenue trend over the past few quarters. For instance, sales recorded in June 2023 stood at ₹592 Cr, declining to ₹578 Cr in September 2023 and further to ₹538 Cr by December 2023. This decline is notable compared to the previous year’s figures, where sales peaked at ₹696 Cr in March 2023. The total sales for the fiscal year ending March 2023 were ₹2,498 Cr, while the trailing twelve months (TTM) revenue is reported at ₹2,237 Cr. This reflects a decline from the previous fiscal year’s sales of ₹2,267 Cr for March 2024, indicating challenges in maintaining revenue momentum. The company’s operational performance, characterized by an operating profit margin (OPM) of 12%, suggests that while sales have faced pressures, the company has managed to maintain a stable margin, which is critical for operational sustainability in the competitive pharma sector.
Profitability and Efficiency Metrics
Aarti Drugs Limited reported a net profit of ₹190 Cr, translating to a price-to-earnings (P/E) ratio of 19.8. The company’s return on equity (ROE) stood at 13.0%, while return on capital employed (ROCE) was slightly higher at 13.5%. The net profit margin for the fiscal year ending March 2025 was recorded at 7.04%, showing a slight improvement from 6.78% in the previous year. Despite these figures indicating reasonable profitability, the operating profit has shown a downward trend, particularly with the operating profit of ₹265 Cr for March 2025, down from ₹321 Cr in March 2022. The cash conversion cycle (CCC) of 127 days highlights operational efficiency challenges, as it indicates the time taken to convert inventory and receivables into cash. The interest coverage ratio (ICR) of 8.46x suggests that the company has sufficient earnings to cover its interest expenses, providing a cushion against financial distress. However, the declining net profit and OPM raise concerns regarding future profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Aarti Drugs Limited reflects a conservative financial structure with total borrowings of ₹440 Cr against reserves of ₹1,250 Cr. This results in a debt-to-equity ratio of 0.44, indicating a moderate level of leverage compared to industry standards. The company’s fixed assets stood at ₹761 Cr, with a book value per share of ₹149.99, reflecting a P/BV ratio of 2.27x, which is relatively low against typical sector benchmarks. The company has maintained a current ratio of 1.60, suggesting healthy short-term liquidity, while the quick ratio stands at 1.03, indicating sufficient liquid assets to cover current liabilities. Additionally, the working capital days have remained stable at 79 days, aligning with industry norms. However, the declining trend in total assets, which stood at ₹2,273 Cr in March 2025, compared to ₹2,196 Cr in March 2023, may raise concerns regarding growth prospects and asset efficiency, necessitating strategic asset management to enhance returns.
Shareholding Pattern and Investor Confidence
Aarti Drugs Limited’s shareholding pattern reveals a substantial promoter stake of 54.72%, which has shown a gradual decline from 59.66% in December 2022, indicating potential dilution of control. Foreign institutional investors (FIIs) hold a modest 2.68%, while domestic institutional investors (DIIs) account for 9.90% of the total shareholding. The public holds 32.70% of the shares, with the total number of shareholders reported at 1,52,252. This diverse ownership structure indicates a level of investor confidence, although the decreasing promoter stake may cause apprehension among investors regarding long-term commitment. The dividend payout ratio has remained stable at around 6%, reflecting a commitment to returning value to shareholders, albeit lower than historical highs. The gradual increase in DII holdings from 3.90% in December 2022 to 9.90% in September 2025 may signal growing institutional interest, which could bolster confidence in the company’s future prospects.
Outlook, Risks, and Final Insight
The outlook for Aarti Drugs Limited presents both opportunities and risks. On the one hand, the company maintains a robust operational framework evidenced by its consistent ROCE and ICR, which provide a buffer against financial instability. However, declining sales and profitability metrics raise concerns over its competitive position in the pharmaceutical market. The challenges associated with maintaining revenue growth, coupled with a high cash conversion cycle, may hinder operational efficiency. Additionally, the fluctuating promoter stake could impact investor confidence. Aarti Drugs must prioritize strategic initiatives to enhance revenue streams and manage operational costs effectively. Focus on innovation and expanding product lines could be crucial for capturing market share. Should the company successfully navigate these challenges, it could leverage its financial stability to capitalize on growth opportunities in the pharmaceutical sector, potentially improving both profitability and shareholder value in the long run.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 231/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,792 Cr. | 441 | 479/192 | 99.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.8 Cr. | 48.2 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.7 Cr. | 36.0 | 36.6/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,119.86 Cr | 1,145.79 | 53.32 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 551 | 625 | 626 | 696 | 592 | 578 | 538 | 560 | 493 | 543 | 515 | 623 | 521 |
| Expenses | 496 | 555 | 557 | 608 | 520 | 512 | 478 | 490 | 439 | 484 | 454 | 534 | 457 |
| Operating Profit | 55 | 70 | 69 | 89 | 72 | 65 | 60 | 69 | 54 | 60 | 60 | 89 | 64 |
| OPM % | 10% | 11% | 11% | 13% | 12% | 11% | 11% | 12% | 11% | 11% | 12% | 14% | 12% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 11 | 2 | 0 |
| Interest | 7 | 8 | 9 | 8 | 8 | 8 | 7 | 8 | 7 | 7 | 8 | 7 | 7 |
| Depreciation | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Profit before tax | 36 | 50 | 49 | 69 | 53 | 47 | 43 | 50 | 35 | 41 | 52 | 71 | 45 |
| Tax % | 28% | 27% | 25% | 23% | 25% | 26% | 26% | 27% | 23% | 26% | 26% | 13% | -7% |
| Net Profit | 26 | 37 | 37 | 53 | 40 | 35 | 32 | 36 | 27 | 30 | 39 | 61 | 49 |
| EPS in Rs | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.31 | 4.19 | 6.69 | 5.29 |
Last Updated: August 2, 2025, 12:55 am
Below is a detailed analysis of the quarterly data for Aarti Drugs Limited based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 521.00 Cr.. The value appears to be declining and may need further review. It has decreased from 623.00 Cr. (Mar 2025) to 521.00 Cr., marking a decrease of 102.00 Cr..
- For Expenses, as of Jun 2025, the value is 457.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 534.00 Cr. (Mar 2025) to 457.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 89.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 25.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 12.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 26.00 Cr..
- For Tax %, as of Jun 2025, the value is -7.00%. The value appears to be improving (decreasing) as expected. It has decreased from 13.00% (Mar 2025) to -7.00%, marking a decrease of 20.00%.
- For Net Profit, as of Jun 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 12.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.29. The value appears to be declining and may need further review. It has decreased from 6.69 (Mar 2025) to 5.29, marking a decrease of 1.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | 2,267 | 2,174 | 2,237 |
| Expenses | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,212 | 1,998 | 1,908 | 1,949 |
| Operating Profit | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 286 | 269 | 265 | 288 |
| OPM % | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% | 12% | 12% | 13% |
| Other Income | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | 4 | 14 | 14 |
| Interest | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 36 | 33 | 32 | 28 |
| Depreciation | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 | 48 | 48 | 50 |
| Profit before tax | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 | 192 | 199 | 224 |
| Tax % | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% | 26% | 21% | |
| Net Profit | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 | 142 | 157 | 190 |
| EPS in Rs | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 | 15.43 | 17.24 | 20.87 |
| Dividend Payout % | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.81% | -15.38% | 13.64% | -2.67% | 19.18% | 56.32% | 89.71% | -24.42% | -21.54% | -7.19% | 10.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.19% | 29.02% | -16.30% | 21.84% | 37.14% | 33.38% | -114.12% | 2.88% | 14.35% | 17.75% |
Aarti Drugs Limited has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 4% |
| 3 Years: | -7% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 10:00 pm
Balance Sheet
Last Updated: December 4, 2025, 12:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 239 | 279 | 326 | 363 | 410 | 495 | 598 | 766 | 880 | 1,022 | 1,083 | 1,160 | 1,250 |
| Borrowings | 342 | 435 | 465 | 448 | 517 | 471 | 378 | 336 | 519 | 535 | 475 | 516 | 440 |
| Other Liabilities | 257 | 228 | 240 | 281 | 366 | 384 | 471 | 442 | 543 | 546 | 522 | 506 | 463 |
| Total Liabilities | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
| Fixed Assets | 373 | 431 | 463 | 542 | 564 | 586 | 612 | 631 | 649 | 634 | 722 | 761 | 970 |
| CWIP | 8 | 13 | 34 | 14 | 28 | 32 | 11 | 16 | 60 | 161 | 222 | 273 | 92 |
| Investments | 5 | 11 | 11 | 18 | 17 | 19 | 20 | 24 | 28 | 29 | 30 | 42 | 53 |
| Other Assets | 464 | 511 | 547 | 541 | 707 | 736 | 828 | 966 | 1,297 | 1,372 | 1,198 | 1,196 | 1,130 |
| Total Assets | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
Below is a detailed analysis of the balance sheet data for Aarti Drugs Limited based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,250.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,160.00 Cr. (Mar 2025) to 1,250.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 440.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 516.00 Cr. (Mar 2025) to 440.00 Cr., marking a decrease of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 463.00 Cr.. The value appears to be improving (decreasing). It has decreased from 506.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 970.00 Cr.. The value appears strong and on an upward trend. It has increased from 761.00 Cr. (Mar 2025) to 970.00 Cr., marking an increase of 209.00 Cr..
- For CWIP, as of Sep 2025, the value is 92.00 Cr.. The value appears to be declining and may need further review. It has decreased from 273.00 Cr. (Mar 2025) to 92.00 Cr., marking a decrease of 181.00 Cr..
- For Investments, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,196.00 Cr. (Mar 2025) to 1,130.00 Cr., marking a decrease of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
Notably, the Reserves (1,250.00 Cr.) exceed the Borrowings (440.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -192.00 | -263.00 | -289.00 | -269.00 | -332.00 | -268.00 | -130.00 | 68.00 | -198.00 | -249.00 | -206.00 | -251.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 103 | 109 | 93 | 117 | 110 | 104 | 96 | 115 | 117 | 104 | 118 |
| Inventory Days | 71 | 77 | 87 | 101 | 132 | 86 | 107 | 125 | 120 | 102 | 107 | 106 |
| Days Payable | 84 | 75 | 85 | 91 | 125 | 86 | 110 | 94 | 103 | 89 | 96 | 97 |
| Cash Conversion Cycle | 91 | 105 | 110 | 103 | 124 | 109 | 101 | 127 | 133 | 130 | 115 | 127 |
| Working Capital Days | -10 | 13 | 21 | 26 | 33 | 46 | 60 | 83 | 68 | 73 | 79 | 79 |
| ROCE % | 22% | 21% | 18% | 17% | 17% | 17% | 20% | 33% | 21% | 15% | 14% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 6,387,722 | 1.6 | 271.38 | 4,636,377 | 2025-12-07 00:37:57 | 37.77% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,453,383 | 0.96 | 61.75 | 1,488,255 | 2025-12-15 01:11:57 | -2.34% |
| DSP Healthcare Fund | 852,155 | 1.14 | 36.2 | 737,671 | 2025-12-07 01:59:04 | 15.52% |
| DSP Value Fund | 70,308 | 0.24 | 2.99 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Diluted EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Cash EPS (Rs.) | 24.53 | 24.26 | 23.40 | 27.54 | 35.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Revenue From Operations / Share (Rs.) | 261.54 | 275.04 | 293.31 | 268.75 | 231.20 |
| PBDIT / Share (Rs.) | 33.24 | 34.86 | 33.24 | 36.80 | 47.38 |
| PBIT / Share (Rs.) | 27.13 | 29.26 | 27.81 | 31.39 | 42.03 |
| PBT / Share (Rs.) | 23.20 | 25.62 | 24.21 | 29.15 | 39.59 |
| Net Profit / Share (Rs.) | 18.42 | 18.66 | 17.97 | 22.14 | 30.09 |
| NP After MI And SOA / Share (Rs.) | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 |
| PBDIT Margin (%) | 12.71 | 12.67 | 11.33 | 13.69 | 20.49 |
| PBIT Margin (%) | 10.37 | 10.64 | 9.47 | 11.68 | 18.18 |
| PBT Margin (%) | 8.87 | 9.31 | 8.25 | 10.84 | 17.12 |
| Net Profit Margin (%) | 7.04 | 6.78 | 6.12 | 8.23 | 13.01 |
| NP After MI And SOA Margin (%) | 7.04 | 6.77 | 6.12 | 8.23 | 13.01 |
| Return on Networth / Equity (%) | 12.28 | 13.37 | 13.94 | 19.78 | 30.69 |
| Return on Capital Employeed (%) | 14.25 | 16.43 | 17.29 | 22.92 | 33.46 |
| Return On Assets (%) | 6.53 | 7.04 | 6.86 | 9.28 | 15.87 |
| Long Term Debt / Equity (X) | 0.20 | 0.21 | 0.17 | 0.13 | 0.16 |
| Total Debt / Equity (X) | 0.44 | 0.43 | 0.50 | 0.51 | 0.33 |
| Asset Turnover Ratio (%) | 0.95 | 1.04 | 1.17 | 1.18 | 1.19 |
| Current Ratio (X) | 1.60 | 1.66 | 1.60 | 1.48 | 1.77 |
| Quick Ratio (X) | 1.03 | 1.05 | 1.05 | 0.92 | 1.08 |
| Inventory Turnover Ratio (X) | 4.98 | 3.14 | 3.39 | 3.37 | 3.15 |
| Dividend Payout Ratio (NP) (%) | 5.42 | 5.36 | 5.56 | 4.51 | 8.30 |
| Dividend Payout Ratio (CP) (%) | 4.07 | 4.12 | 4.27 | 3.63 | 7.05 |
| Earning Retention Ratio (%) | 94.58 | 94.64 | 94.44 | 95.49 | 91.70 |
| Cash Earning Retention Ratio (%) | 95.93 | 95.88 | 95.73 | 96.37 | 92.95 |
| Interest Coverage Ratio (X) | 8.46 | 9.56 | 9.25 | 16.42 | 19.24 |
| Interest Coverage Ratio (Post Tax) (X) | 5.69 | 6.12 | 6.00 | 10.88 | 13.20 |
| Enterprise Value (Cr.) | 3706.38 | 4541.99 | 3725.82 | 4488.49 | 6770.51 |
| EV / Net Operating Revenue (X) | 1.55 | 1.80 | 1.37 | 1.80 | 3.14 |
| EV / EBITDA (X) | 12.22 | 14.17 | 12.10 | 13.17 | 15.33 |
| MarketCap / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| Retention Ratios (%) | 94.57 | 94.63 | 94.43 | 95.48 | 91.69 |
| Price / BV (X) | 2.27 | 3.11 | 2.62 | 3.83 | 7.09 |
| Price / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| EarningsYield | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 |
After reviewing the key financial ratios for Aarti Drugs Limited, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.53. This value is within the healthy range. It has increased from 24.26 (Mar 24) to 24.53, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 261.54. It has decreased from 275.04 (Mar 24) to 261.54, marking a decrease of 13.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 33.24. This value is within the healthy range. It has decreased from 34.86 (Mar 24) to 33.24, marking a decrease of 1.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 27.13. This value is within the healthy range. It has decreased from 29.26 (Mar 24) to 27.13, marking a decrease of 2.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.20. This value is within the healthy range. It has decreased from 25.62 (Mar 24) to 23.20, marking a decrease of 2.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 18.42, marking a decrease of 0.24.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.65 (Mar 24) to 18.42, marking a decrease of 0.23.
- For PBDIT Margin (%), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 12.71, marking an increase of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 10.37. This value is within the healthy range. It has decreased from 10.64 (Mar 24) to 10.37, marking a decrease of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 10. It has decreased from 9.31 (Mar 24) to 8.87, marking a decrease of 0.44.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 6.78 (Mar 24) to 7.04, marking an increase of 0.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 6.77 (Mar 24) to 7.04, marking an increase of 0.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.28. This value is below the healthy minimum of 15. It has decreased from 13.37 (Mar 24) to 12.28, marking a decrease of 1.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.25. This value is within the healthy range. It has decreased from 16.43 (Mar 24) to 14.25, marking a decrease of 2.18.
- For Return On Assets (%), as of Mar 25, the value is 6.53. This value is within the healthy range. It has decreased from 7.04 (Mar 24) to 6.53, marking a decrease of 0.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.20, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.44, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has decreased from 1.04 (Mar 24) to 0.95, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has decreased from 1.66 (Mar 24) to 1.60, marking a decrease of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 1.05 (Mar 24) to 1.03, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 3.14 (Mar 24) to 4.98, marking an increase of 1.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.42. This value is below the healthy minimum of 20. It has increased from 5.36 (Mar 24) to 5.42, marking an increase of 0.06.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.07. This value is below the healthy minimum of 20. It has decreased from 4.12 (Mar 24) to 4.07, marking a decrease of 0.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.58. This value exceeds the healthy maximum of 70. It has decreased from 94.64 (Mar 24) to 94.58, marking a decrease of 0.06.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.93. This value exceeds the healthy maximum of 70. It has increased from 95.88 (Mar 24) to 95.93, marking an increase of 0.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 9.56 (Mar 24) to 8.46, marking a decrease of 1.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.69. This value is within the healthy range. It has decreased from 6.12 (Mar 24) to 5.69, marking a decrease of 0.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,706.38. It has decreased from 4,541.99 (Mar 24) to 3,706.38, marking a decrease of 835.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.55, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 12.22. This value is within the healthy range. It has decreased from 14.17 (Mar 24) to 12.22, marking a decrease of 1.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 94.57. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.57, marking a decrease of 0.06.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 3.11 (Mar 24) to 2.27, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Drugs Limited:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.9 (Industry average Stock P/E: 53.32)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 198, M.I.D.C., Palghar District Maharashtra 401506 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant V Gogri | Chairman Emeritus |
| Mr. Prakash M Patil | Chairman & M.D & CEO |
| Mr. Rashesh C Gogri | Managing Director |
| Mr. Harshit M Savla | Joint Managing Director |
| Mr. Harit P Shah | Executive Director |
| Mr. Uday M Patil | Executive Director |
| Mr. Narendra J Salvi | Non Executive Director |
| Mr. Ankit V Paleja | Independent Director |
| Prof. Bhaskar N Thorat | Independent Director |
| Mrs. Neha R Gada | Independent Director |
| Mr. Hasmukh B Dedhia | Independent Director |
| Mr. Sandeep M Joshi | Independent Director |
| Mr. Ajit E Venugopalan | Independent Director |
FAQ
What is the intrinsic value of Aarti Drugs Limited?
Aarti Drugs Limited's intrinsic value (as of 01 January 2026) is ₹304.96 which is 26.69% lower the current market price of ₹416.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,796 Cr. market cap, FY2025-2026 high/low of ₹575/312, reserves of ₹1,250 Cr, and liabilities of ₹2,245 Cr.
What is the Market Cap of Aarti Drugs Limited?
The Market Cap of Aarti Drugs Limited is 3,796 Cr..
What is the current Stock Price of Aarti Drugs Limited as on 01 January 2026?
The current stock price of Aarti Drugs Limited as on 01 January 2026 is ₹416.
What is the High / Low of Aarti Drugs Limited stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Drugs Limited stocks is ₹575/312.
What is the Stock P/E of Aarti Drugs Limited?
The Stock P/E of Aarti Drugs Limited is 19.9.
What is the Book Value of Aarti Drugs Limited?
The Book Value of Aarti Drugs Limited is 147.
What is the Dividend Yield of Aarti Drugs Limited?
The Dividend Yield of Aarti Drugs Limited is 0.24 %.
What is the ROCE of Aarti Drugs Limited?
The ROCE of Aarti Drugs Limited is 13.5 %.
What is the ROE of Aarti Drugs Limited?
The ROE of Aarti Drugs Limited is 13.0 %.
What is the Face Value of Aarti Drugs Limited?
The Face Value of Aarti Drugs Limited is 10.0.